Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q14141
UPID:
SEPT6_HUMAN
Alternative names:
-
Alternative UPACC:
Q14141; Q5JTK0; Q969W5; Q96A13; Q96GR1; Q96P86; Q96P87
Background:
Septin-6, a filament-forming cytoskeletal GTPase, plays a crucial role in the organization of the actin cytoskeleton and cytokinesis. It is essential for HCV RNA replication and forms a complex with SEPTIN12, SEPTIN6, SEPTIN2, and SEPTIN4, vital for sperm tail integrity and motility.
Therapeutic significance:
Understanding the role of Septin-6 could open doors to potential therapeutic strategies.